These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21843305)

  • 21. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice.
    Schreiber SA; Ferlinz K; Haak T
    Diabetes Technol Ther; 2008 Apr; 10(2):121-7. PubMed ID: 18260775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
    Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
    Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V; Gill J; Zhou R; Leahy J
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).
    Ratner R; Wynne A; Nakhle S; Brusco O; Vlajnic A; Rendell M
    Diabetes Obes Metab; 2011 Dec; 13(12):1142-8. PubMed ID: 21812890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
    Ligthelm RJ
    Prim Care Diabetes; 2009 May; 3(2):97-102. PubMed ID: 19285933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
    Hanefeld M; Koehler C; Hoffmann C; Wilhelm K; Kamke W; Gerstein H
    Diabet Med; 2010 Feb; 27(2):175-80. PubMed ID: 20546261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
    Karl D; Zhou R; Vlajnic A; Riddle M
    Diabet Med; 2012 Jul; 29(7):933-6. PubMed ID: 22413808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for insulin initiation: insights from the French LIGHT observational study.
    Vergès B; Brun JM; Tawil C; Alexandre B; Kerlan V
    Diabetes Metab Res Rev; 2012 Jan; 28(1):97-105. PubMed ID: 22218757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Honka M; Ackermann RW; Meriläinen M; Gallwitz B; Sreenan S;
    Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
    Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
    Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.